[CYTK] Cytokinetics, Incorporated

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 384.31 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 12.4 Change: 0.6 (5.08%)
Ext. hours: Change: 0 (0%)

chart CYTK

Refresh chart

Strongest Trends Summary For CYTK

CYTK is in the medium-term down -37% below S&P in 1 year.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Cytokinetics, Incorporated, a clinical stage biopharmaceutical company, focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the treatment of heart failure. The company holds a license to develop and commercialize omecamtiv mecarbil and related compounds worldwide. It develops tirasemtiv, a fast skeletal muscle activator, as a potential treatment for diseases and medical conditions associated with neuromuscular dysfunction. Tirasemtiv is in Phase II clinical trials program and has been granted orphan drug designation and fast track status by the United States Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis. Cytokinetics, Incorporated has a st

Fundamental Ratios
Shares Outstanding39.62 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -43.32% Sales Growth - Q/Q-79.71% P/E
P/E To EPS Growth P/S8.86 P/BV4.57 Price/Cash Per Share3.56
Price/Free Cash Flow-8.36 ROA-12.09% ROE-17.56% ROI
Current Ratio4.37 Quick Ratio Long Term Debt/Equity Debt Ratio0.3
Gross Margin Operating Margin-34.34% Net Profit Margin-34.06% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities70 K Cash From Investing Activities-32.09 M Cash From Operating Activities34.36 M Gross Profit
Net Profit-8.87 M Operating Profit-8.91 M Total Assets122.21 M Total Current Assets110.81 M
Total Current Liabilities25.39 M Total Debt Total Liabilities38.06 M Total Revenue4.41 M
Technical Data
High 52 week14.25 Low 52 week5.91 Last close9.55 Last change3.24%
RSI30.56 Average true range0.71 Beta1.3 Volume193.45 K
Simple moving average 20 days-3.05% Simple moving average 50 days-13.73% Simple moving average 200 days-7.83%
Performance Data
Performance Week17.9% Performance Month-15.93% Performance Quart-29.05% Performance Half-0.21%
Performance Year37.41% Performance Year-to-date51.11% Volatility daily6.53% Volatility weekly14.61%
Volatility monthly29.94% Volatility yearly103.71% Relative Volume217.31% Average Volume661.66 K
New High New Low

News

2020-05-27 07:30:10 | Cytokinetics and The ALS Association Renew Partnership to Advance the Fight Against ALS

2020-05-11 12:21:00 | Here's Why Cytokinetics Is Skyrocketing 24.5% Today

2020-05-11 12:21:00 | Here's Why Cytokinetics Is Skyrocketing 24.5% Today

2020-05-08 08:30:10 | FDA Grants Fast Track Designation for Omecamtiv Mecarbil in Heart Failure

2020-05-07 16:00:54 | Cytokinetics Inc CYTK Q1 2020 Earnings Call Transcript

2020-05-07 16:00:10 | Cytokinetics to Hold Annual Meeting of Stockholders

2020-05-07 13:18:14 | Edited Transcript of CYTK earnings conference call or presentation 6-May-20 8:30pm GMT

2020-05-06 16:00:10 | Cytokinetics Reports First Quarter 2020 Financial Results

2020-05-05 11:46:20 | 3 Biotech Stocks With Plenty of Upside in the Pipeline

2020-05-04 17:59:35 | Cytokinetics Trading at Half High Target of $30

2020-05-04 07:58:03 | Is Cytokinetics, Incorporated NASDAQ:CYTK Excessively Paying Its CEO?

2020-04-30 08:33:20 | 3 Monster Growth Stocks With Still Plenty of Gas in the Tank

2020-04-29 12:34:04 | Cytokinetics CYTK Expected to Beat Earnings Estimates: Can the Stock Move Higher?

2020-04-22 16:00:10 | Cytokinetics to Announce First Quarter Results on May 6, 2020

2020-04-14 07:30:10 | Cytokinetics Provides Clinical Trials and Business Update in Response to COVID-19 Pandemic

2020-04-08 16:00:10 | Cytokinetics to Participate in the 19th Annual Needham Virtual Healthcare Conference

2020-03-30 13:35:05 | Correction: Cytokinetics Announces Baseline Characteristics from GALACTIC-HF at ACC.20/WCC Virtual

2020-03-30 07:30:10 | Cytokinetics Announces Baseline Characteristics from GALACTIC-HF at ACC.20/WCC Virtual

2020-03-20 16:00:10 | CYTOKINETICS TO ANNOUNCE BASELINE CHARACTERISTICS FROM GALACTIC-HF DURING ACC.20/WCC

2020-03-04 07:30:10 | Cytokinetics Granted European Orphan Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis

2020-03-04 01:35:56 | Edited Transcript of CYTK earnings conference call or presentation 3-Mar-20 9:30pm GMT

2020-03-03 17:15:10 | Cytokinetics CYTK Reports Q4 Loss, Misses Revenue Estimates

2020-03-03 16:00:10 | Cytokinetics Reports Fourth Quarter 2019 Financial Results

2020-03-03 07:30:10 | Cytokinetics Announces Preclinical Data for AMG 594 Presented at the Keystone Symposium on Heart Failure

2020-02-28 07:30:10 | Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day

2020-02-26 08:30:10 | Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis

2020-02-25 12:30:05 | Cytokinetics CYTK May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

2020-02-20 07:30:10 | Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the Biophysical Society 64th Annual Meeting

2020-02-18 16:00:10 | Cytokinetics to Announce Fourth Quarter Results on March 3, 2020

2020-02-13 12:31:05 | Cytokinetics CYTK May Report Negative Earnings: Know the Trend Ahead of Q4 Release

2020-02-12 10:55:30 | Small-Cap Healthcare ETF Outperforming in 2020: 5 Top Stocks

2020-02-06 04:30:10 | Cytokinetics Announces Publication Relating to Design of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure

2020-01-30 06:59:41 | Cytokinetics, Incorporated NASDAQ:CYTK: What Does Its Beta Value Mean For Your Portfolio?

2020-01-22 07:30:10 | Cytokinetics Announces Recipients of Second Annual Communications Fellowship Grants

2020-01-17 09:26:02 | Implied Volatility Surging for Cytokinetics CYTK Stock Options

2020-01-13 07:30:10 | Cytokinetics Announces Vision 2025 and Outlines 2020 Corporate Milestones

2020-01-10 20:10:00 | Wall Street Views on American Water Works, Royal Caribbean and Others

2020-01-06 07:30:10 | Cytokinetics Announces Start of Redwood-HCM, a Phase 2 Clinical Trial of CK-3773274

2020-01-03 17:43:31 | 2020 Preview: The year ahead in Bay Area biotech and health

2019-12-18 07:30:10 | Cytokinetics Granted Orphan Drug Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis

2019-12-10 10:45:28 | Is Cytokinetics, Incorporated CYTK A Good Stock To Buy?

2019-12-09 10:03:27 | World's largest biotech company to move up to BioMed's big South City project

2019-12-09 10:03:27 | World's largest biotech company to move up to BioMed's big South City project

2019-12-05 07:30:10 | Cytokinetics Announces New Results Presented at the International Symposium on ALS/MND

2019-11-27 16:00:10 | Cytokinetics to Participate in the Piper Jaffray Healthcare Conference

2019-11-27 09:45:31 | 5 “Strong Buy” Biotech Stocks With More Than 80% Upside

2019-11-26 16:00:10 | Cytokinetics Announces Five Presentations at the International Symposium on ALS/MND

2019-11-18 09:00:00 | New Results From COSMIC-HF Presented at AHA 2019 Show Treatment of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral or Improved Measures of Diastolic Function

2019-11-11 09:00:00 | Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at the American Heart Association Scientific Sessions 2019

2019-11-08 07:30:00 | Cytokinetics Announces Pricing of Public Offering of Convertible Senior Notes